FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 227 filers reported holding FATE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $81,060 | -71.7% | 38,236 | -36.5% | 0.01% | -71.0% |
| Q2 2023 | $286,723 | +77.5% | 60,236 | +112.6% | 0.03% | +55.0% |
| Q1 2023 | $161,515 | -14.6% | 28,336 | +51.2% | 0.02% | -28.6% |
| Q4 2022 | $189,046 | -43.1% | 18,736 | +26.3% | 0.03% | -58.2% |
| Q3 2022 | $332,000 | -36.0% | 14,836 | +135.5% | 0.07% | -43.7% |
| Q1 2021 | $519,000 | – | 6,300 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |